Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded

Samaratunga H, Delahunt B, Egevad L, Srigley JR, Billis A, Bostwick DG, Camparo P, Cheng L, Clouston D, Denham J, Furusato B, Hartmann A, Jufe L, Kench J, Kenwright DN, Kristiansen G, Leite KRM, Maclennan GT, Merrimen J, Moch H, Oxley J, Pan CC, Paner G, Ro J, Sesterhenn IAM, Shanks J, Thunders M, Tsuzuki T, Wheeler T, Yaxley JW, Varma M (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 52

Pages Range: 192-196

Journal Issue: 2

DOI: 10.1016/j.pathol.2019.11.001

Abstract

Infiltration of the prostatic ducts by prostatic adenocarcinoma occurs relatively frequently, being most commonly associated with high grade disease. It is now recognised that intraductal carcinoma of the prostate (IDCP) has an associated poor prognosis and this is reflected in its histological, molecular and immunohistochemical features. The current recommendation of the World Health Organization is that IDCP not be taken into consideration when grading prostate adenocarcinoma. It is apparent that Gleason did not differentiate between IDCP and stromal invasive carcinoma when developing and validating his grading system, and recent studies suggest that the incorporation of IDCP grading into the overall grading of the specimen provides additional prognostic information.

Authors with CRIS profile

Involved external institutions

University of Zurich / Universität Zürich (UZH) Switzerland (CH) North Bristol NHS Trust United Kingdom (GB) Taipei Veterans General Hospital / 台北榮民總醫院 Taiwan (TW) University of Chicago United States (USA) (US) Cornell University United States (USA) (US) Aquesta Specialized Uropathology Australia (AU) University of Otago New Zealand (NZ) Karolinska Institute Sweden (SE) University of Toronto Canada (CA) Universidade Estadual de Campinas (UNICAMP) / University of Campinas Brazil (BR) Bostwick Laboratories United States (USA) (US) Centre de Pathologie des Hauts-de-France France (FR) Indiana University – Purdue University Indianapolis United States (USA) (US) Tissupath Australia (AU) University of Newcastle (UoN) Australia (AU) Nagasaki University Japan (JP) Hospital General de Agudos José María Ramos Mejía Argentina (AR) University of Sydney (USYD) Australia (AU) Universitätsklinikum Bonn Germany (DE) University of São Paulo / Universidade de São Paulo (USP) Brazil (BR) Case Western Reserve University United States (USA) (US) Queen Elizabeth II Health Sciences Centre Canada (CA) The Joint Pathology Center (JPC) United States (USA) (US) Christie NHS Foundation Trust United Kingdom (GB) Aichi Medical University / 愛知医科大学 Japan (JP) Houston Texas Medical Center United States (USA) (US) University of Queensland Australia (AU) Cardiff and Vale University Health Board United Kingdom (GB)

How to cite

APA:

Samaratunga, H., Delahunt, B., Egevad, L., Srigley, J.R., Billis, A., Bostwick, D.G.,... Varma, M. (2020). Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 52(2), 192-196. https://doi.org/10.1016/j.pathol.2019.11.001

MLA:

Samaratunga, Hemamali, et al. "Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded." Pathology 52.2 (2020): 192-196.

BibTeX: Download